Maria Roberta Cilio

Maria Roberta Cilio

Auto-generated profile, based on publicly available information

Maria Roberta Cilio

Institute of Neuroscience Université catholique de Louvain Brussels Belgium

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Epilepsia
Verified
Journal Article
Closed access
PDF file
RPRonit M. Pressler
Ronit M. Pressler
MCMaria Roberta Cilio
Maria Roberta Cilio
EMEli M. Mizrahi
Eli M. Mizrahi
SMSolomon L. Moshé
Solomon L. Moshé
MNMagda Lahorgue Nunes
Magda Lahorgue Nunes
SZSameer M. Zuberi
Sameer M. Zuberi

1 September 2023 in Epilepsia
Verified
Journal Article
Open access
RPRonit M. Pressler
Ronit M. Pressler
NANicholas S. Abend
Nicholas S. Abend
SAStéphan Auvin
Stéphan Auvin
GBGeraldine Boylan
Geraldine Boylan
Francesco BrigoFrancesco Brigo
Francesco Brigo
HHHans Hartmann
Hans Hartmann
Seizures are common in neonates, but there is substantial management variability. The Neonatal Task Force of the International League Against Epilepsy (ILAE) developed evidence‐based recommendations about antiseizure medication (ASM) management in neonates in accordance with ILAE standards. Six priority questions were formulated, a systematic literature review and meta‐analysis were performed, and results were reported following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) 2020 standards. Bias was evaluated using the Cochrane tool and risk of Bias in non‐randomised studies ‐ of interventions (ROBINS‐I), and quality of evidence was evaluated using grading of recommendations, assessment, development and evaluation (GRADE). If insufficient evidence was available, then expert opinion was sought using Delphi consensus methodology. The strength of recommendations was defined according to the ILAE Clinical Practice Guidelines development tool. There were six main recommendations. First, phenobarbital should be the first‐line ASM (evidence‐based recommendation) regardless of etiology (expert agreement), unless channelopathy is likely the cause for seizures (e.g., due to family history), in which case phenytoin or carbamazepine should be used. Second, among neonates with seizures not responding to first‐line ASM, phenytoin, levetiracetam, midazolam, or lidocaine may be used as a second‐line ASM (expert agreement). In neonates with cardiac disorders, levetiracetam may be the preferred second‐line ASM (expert agreement). Third, following cessation of acute provoked seizures without evidence for neonatal‐onset epilepsy, ASMs should be discontinued before discharge home, regardless of magnetic resonance imaging or electroencephalographic findings (expert agreement). Fourth, therapeutic hypothermia may reduce seizure burden in neonates with hypoxic–ischemic encephalopathy (evidence‐based recommendation). Fifth, treating neonatal seizures (including electrographic‐only seizures) to achieve a lower seizure burden may be associated with improved outcome (expert agreement). Sixth, a trial of pyridoxine may be attempted in neonates presenting with clinical features of vitamin B6‐dependent epilepsy and seizures unresponsive to second‐line ASM (expert agreement). Additional considerations include a standardized pathway for the management of neonatal seizures in each neonatal unit and informing parents/guardians about the diagnosis of seizures and initial treatment options.

8 June 2019 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
TSTristan T. Sands
Tristan T. Sands
FMFrancesco Miceli
Francesco Miceli
GLGaetan Lesca
Gaetan Lesca
ABAnita E. Beck
Anita E. Beck
LSLynette G. Sadleir
Lynette G. Sadleir
MCM. Roberta Cilio
M. Roberta Cilio

2 May 2019 in CNS Drugs
Verified
Journal Article
Open access
PDF file
JWJames W. Wheless
James W. Wheless
DDDennis Dlugos
Dennis Dlugos
IMIan Miller
Ian Miller
DOD. Alexander Oh
D. Alexander Oh
NPNeha Parikh
Neha Parikh
MCMaria Roberta Cilio
Maria Roberta Cilio
Background Prior studies have evaluated the use of various constituents of cannabis for their anti-seizure effects. Specifically, cannabidiol, a non-psychoactive component of cannabis, has been investigated for treatment-resistant epilepsy, but more information is needed particularly on its use in a pediatric population. Objective The objective of this study was to evaluate the pharmacokinetics and safety of a synthetic pharmaceutical-grade cannabidiol oral solution in pediatric patients with treatment-resistant epilepsy. Methods In this open-label study, pediatric patients (aged 1 to ≤ 17 years) with treatment-resistant epilepsy received cannabidiol oral solution administered as add-on to their current antiepileptic drug regimen. Patients received a single dose (5, 10, or 20 mg/kg) on day 1 and twice-daily dosing on days 4 through 10 (10-mg/kg [cohort 1], 20-mg/kg [cohort 2], or 40-mg/kg [cohort 3] total daily dose). Serial blood samples were collected on day 1 before dosing and up to 72 h post-dose, and on day 10 before dosing and up to 24 h post-dose. Blood samples to assess trough concentrations of cannabidiol were collected on day 6 (for patients aged 12 to ≤ 17 years), day 8 (for patients aged 2 to ≤ 17 years), and day 9 (for patients aged 6 to ≤ 17 years). Results Overall, 61 patients across three cohorts received one of three doses of cannabidiol oral solution (mean age, 7.6 years). The age composition was similar in the three cohorts. There was a trend for increased cannabidiol exposure with increased cannabidiol oral solution dosing, but overall exposure varied. Approximately 2–6 days of twice-daily dosing provided steady-state concentrations of cannabidiol. A bi-directional drug interaction occurred with cannabidiol and clobazam. Concomitant administration of clobazam with 40 mg/kg/day of cannabidiol oral solution resulted in a 2.5-fold increase in mean cannabidiol exposure. Mean plasma clobazam concentrations were 1.7- and 2.2-fold greater in patients receiving clobazam concomitantly with 40 mg/kg/day of cannabidiol oral solution compared with 10 mg/kg/day and 20 mg/kg/day. Mean plasma norclobazam values were 1.3- and 1.9-fold higher for patients taking clobazam plus 40 mg/kg/day of cannabidiol oral solution compared with the 10-mg/kg/day and 20-mg/kg/day groups. All doses were generally well tolerated, and common adverse events that occurred at > 10% were somnolence (21.3%), anemia (18.0%), and diarrhea (16.4%). Conclusions Inter-individual variability in systemic cannabidiol exposure after pediatric patient treatment with cannabidiol oral solution was observed but decreased with multiple doses. Short-term administration was generally safe and well tolerated. Trial Registration ClinicalTrials.gov (NCT02324673).

21 June 2021 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MCMarie‐Coralie Cornet
Marie‐Coralie Cornet
VMValeria Morabito
Valeria Morabito
DLDamien Lederer
Damien Lederer
HGHannah C. Glass
Hannah C. Glass
SSSusana Ferrao Santos
Susana Ferrao Santos
MCMaria Roberta Cilio
Maria Roberta Cilio

20 November 2018 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
TSTristan T. Sands
Tristan T. Sands
SRShahryar Rahdari
Shahryar Rahdari
MOMichael S. Oldham
Michael S. Oldham
ENEduardo Caminha Nunes
Eduardo Caminha Nunes
NTNicole Tilton
Nicole Tilton
MCMaria Roberta Cilio
Maria Roberta Cilio